Galidesivir: Island Secures $9M as FDA Greenlights Pathway

Island Pharmaceuticals Secures $9 Million to Advance Galidesivir for Marburg Virus Under US FDA Animal Rule

Australian biopharmaceutical company Island Pharmaceuticals has successfully raised $9 million in new funding, a significant capital injection that will propel its antiviral drug candidate, Galidesivir, through a crucial development pathway under the US Food and Drug Administration’s (FDA) Animal Rule. This strategic funding, spearheaded by a US-based family office and supported by a syndicate of local and international investors, is earmarked to fully finance the clinical development of Galidesivir, paving the way for a New Drug Application (NDA) with the US FDA.

The substantial placement bolsters Island Pharmaceuticals’ (ASX: ILA) existing cash reserves, which stood at $6.87 million as of December 31, 2025. The company asserts that this new capital provides “ample” resources to not only complete the Galidesivir program but also to support the rigorous submission process for the NDA.

Beyond the immediate focus on Marburg virus, the raised funds will also empower Island Pharmaceuticals to advance regulatory and pre-clinical work for additional US Government stockpile opportunities. These initiatives target other high-consequence viral threats, including Ebola and Sudan virus, aligning the company’s efforts with critical biodefence priorities.

Strategic Alignment with US Biodefence and Government Procurement

David Foster, CEO and Managing Director of Island Pharmaceuticals, highlighted the strategic significance of Galidesivir’s alignment with US biodefence objectives. He explained that securing approval under the Animal Rule could unlock eligibility for procurement by the US Government, potentially leading to inclusion in the Strategic National Stockpile. This scenario presents a clear pathway to substantial, non-dilutive government-backed revenue streams for the company.

Furthermore, Foster emphasised the considerable value leverage offered by Galidesivir’s potential qualification for an FDA Tropical Disease Priority Review Voucher (PRV) upon approval via the Animal Rule. The recent valuation of PRV transactions at approximately US$200 million underscores the significant, non-dilutive value this pathway could deliver to shareholders, irrespective of long-term commercial rollout strategies.

FDA Confirms Crucial Development Pathway for Galidesivir

In a significant regulatory development, Island Pharmaceuticals received correspondence from the FDA on January 30, confirming alignment on its proposed Animal Rule trial approach. This confirmation specifically validates key elements of the development framework, including the use of the Angola strain of Marburg virus, the cynomolgus macaque model, and the proposed viral challenge dose. This FDA endorsement represents a major de-risking milestone for the Galidesivir program, providing a clear and validated roadmap for development.

The Animal Rule is a specialised pathway established by the FDA for life-threatening pathogens where human trials are either not feasible or ethically permissible. This includes filoviruses like Marburg, which is responsible for severe and often fatal haemorrhagic fever.

The FDA has now outlined a two-stage clinical development pathway for Galidesivir. The initial stage will concentrate on targeted dose optimisation and pharmacokinetic (PK) studies. This will be followed by a pivotal confirmatory study, a mandatory requirement for regulatory approval. These crucial studies will utilise Island’s first manufactured batch of Galidesivir and will involve a limited number of non-human primates. Data generated from the PK studies will be submitted to the FDA to facilitate progression to the pivotal confirmatory phase.

Advancing Towards Trial Commencement with Leading Partners

With regulatory clarity secured, Island Pharmaceuticals is now finalising arrangements with the Texas Biomedical Research Institute (Texas Biomed) to conduct the Animal Rule studies. This follows the establishment of a Master Service Agreement in December. The company is also actively engaged in discussions with additional partners to further accelerate development timelines.

Texas Biomed holds a distinguished position as one of only four Biosafety Level 4 (BSL-4) facilities in the United States and is the sole private sector facility capable of undertaking preclinical infectious disease research involving non-human primates. BSL-4 laboratories represent the highest level of biosecurity and are essential for research involving highly lethal pathogens that can be easily transmitted and cause severe or fatal human diseases for which no vaccines or treatments currently exist. The institute boasts a robust track record in high-consequence viral research, having contributed to the development of the first COVID-19 vaccine, the first Ebola treatment, and the first Hepatitis C therapy.

Foster expressed his optimism regarding the recent FDA correspondence, describing it as the most explicit regulatory position received to date and a monumental step forward for Galidesivir. “We are now moving from regulatory definition into execution,” he stated. “The upcoming studies are tightly scoped, targeted, and represent the final preparatory work before entering the pivotal confirmatory phase required for approval.”

With funding secured, drug supply manufactured, and premier BSL-4 partners onboard, Island Pharmaceuticals is prioritising disciplined execution of the development plan. “With a clearly defined regulatory roadmap, strong FDA alignment, and funding secured, Island is entering the pivotal phase in the evolution of the Galidesivir program,” Foster concluded. “Our focus is now on execution to unlock the full strategic and commercial potential of this asset.”